Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125886911 | 12588691 | 1 | I | 20160712 | 20160725 | 20160725 | EXP | DK-HQ SPECIALTY-DK-2016INT000645 | INTERCHEM | LAURITSEN J, KIER MGG, BANDAK M, MORTENSEN MS, THOMSEN FB, MORTENSEN J, ET AL. PULMONARY FUNCTION IN PATIENTS WITH GERM CELL CANCER TREATED WITH BLEOMYCIN, ETOPOSIDE, AND CISPLATIN. J CLIN ONCOL. 2016;34 (13):1492-1499 | 0.00 | Y | 0.00000 | 20160725 | MD | DK | DK |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125886911 | 12588691 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | 18057 | ||||||||||
125886911 | 12588691 | 2 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | Unknown | UNK | 0 | ||||||||||
125886911 | 12588691 | 3 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | UNK | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125886911 | 12588691 | 1 | Germ cell cancer |
125886911 | 12588691 | 2 | Germ cell cancer |
125886911 | 12588691 | 3 | Germ cell cancer |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125886911 | 12588691 | DE |
125886911 | 12588691 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125886911 | 12588691 | Pulmonary toxicity | |
125886911 | 12588691 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |